Chromogranin A as a biomarker of disease activity and biologic therapy in inflammatory bowel disease: a prospective observational study

AbstractObjective. To access the correlation of Chromogranin A (CgA) with inflammatory bowel disease (IBD) activity and responsiveness to medical therapy. Material and methods. A prospective observational study was conducted in 56 patients with moderate ulcerative colitis (UC) or Crohn's diseas...

Full description

Saved in:

Bibliographic Details
Published in:	Scandinavian journal of gastroenterology Vol. 49; no. 8; pp. 942 - 949
Main Authors:	Zissimopoulos, Athanasios, Vradelis, Stergios, Konialis, Manolis, Chadolias, Dimitrios, Bampali, Asimenia, Constantinidis, Theodoros, Efremidou, Eleni, Kouklakis, George
Format:	Journal Article
Language:	English
Published:	England Informa Healthcare 01-08-2014 Taylor & Francis
Subjects:	Adalimumab Adult Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Biomarkers - blood Chromogranin A Chromogranin A - blood Colitis, Ulcerative - blood Colitis, Ulcerative - diagnosis Crohn Disease - blood Crohn Disease - diagnosis Crohn's disease Disease Progression Drug Therapy, Combination Female Gastrointestinal Agents - therapeutic use Glucocorticoids - therapeutic use Humans IBD IBS Immunosuppressive Agents - therapeutic use Inflammatory Bowel Diseases - blood Inflammatory Bowel Diseases - diagnosis Inflammatory Bowel Diseases - drug therapy Infliximab Male Middle Aged Predictive Value of Tests Prospective Studies Sensitivity and Specificity Treatment Outcome ulcerative colitis IBD ulcerative colitis Chromogranin A IBS Crohn’s disease
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	AbstractObjective. To access the correlation of Chromogranin A (CgA) with inflammatory bowel disease (IBD) activity and responsiveness to medical therapy. Material and methods. A prospective observational study was conducted in 56 patients with moderate ulcerative colitis (UC) or Crohn's disease (CD) (UC, n = 29, CD, n = 27), 17 patients with irritable bowel syndrome and predominant diarrhea (IBS-D) and 40 healthy volunteers. IBD patients were treated by biologics (infliximab or adalimumab) or conventional agents (aminosalicylates, thiopurines or methotrexate and steroids) and were classified according to their treatment in two groups. Serum CgA was measured at baseline and 4-week posttreatment period. Results. Serum CgA was significantly higher in IBD patients than in those with IBS-D or healthy volunteers (p < 0.01). Furthermore, serum CgA was markedly increased in CD patients than in UC patients (p < 0.01). CgA value was significantly reduced in 'biologic' group (24 IBD patients, UC, n = 15, CD, n = 9) at 4-week posttreatment period (p < 0.01), while 18/24 (72%) patients were already in remission during that time. In contrast, CgA value was significantly increased in the 'conventional' treatment group (32 IBD patients, UC, n = 14, CD, n = 18) between the two visits (p < 0.01), although 22/32 (69%) patients were in remission during the 4-week posttreatment period. Conclusion. CgA appears to be a reliable marker of disease activity in IBD patients and especially in those who received biologic therapy. IBS-D patients presented normal CgA values.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23
ISSN:	0036-5521 1502-7708
DOI:	10.3109/00365521.2014.920910